AbCellera Biologics Inc.
SEC EDGAR quarterly and annual company filings
Past bets that played out
These are the clearest thesis calls with observable outcomes, linked back to the original videos.
The provided text is only the cover/header portion of AbCellera Biologics Inc.’s Form 10‑Q for the quarter ended March 31, 2026 (identifying info, exchange listing, filing status). It contains no financial statements, guidance, risk updates, material events, MD&A, cash runway, pipeline/program updates, or disclosures that would support a differentiated trading view.
The provided 10-K text is only the cover page/registrant identifiers for AbCellera Biologics Inc. (ABCL) for FY ended 2025-12-31. It contains no financial statements, MD&A, risk factor changes, guidance, segment detail, liquidity/cash runway, pipeline/program updates, or other disclosures that would support a directional investment view.
The provided text is only the cover/header portion of AbCellera Biologics Inc.’s Form 10-Q for the quarter ended Sep 30, 2025. It confirms the issuer (ABCL), exchange listing (Nasdaq), and that it indicates timely filing/compliance checks, but contains no financial statements, MD&A, risk-factor updates, guidance, or material events. Actionability is therefore very limited.
What this channel is watching now
Recent mentions show where this author is concentrating attention right now.
Latest videos and market context
Recent source posts from this author. Create an account to inspect the complete persisted research trail.
GEV 10-Q report for 2026-06-30
The provided excerpt is only the Form 10‑Q cover page for GE Vernova Inc. (GEV) for quarter ended 2026‑06‑30, with no financial statements, MD&A, segment results, guidance, backlog, risks, or other performance details included. As-is, it contains almost no trade-relevant incremental information beyond confirming the filing/period and listing details.
SNBR 10-Q report for 2026-04-04
This excerpt is only the cover page/header of Sleep Number’s Form 10-Q for the quarter ended April 4, 2026. It contains filing metadata (issuer, ticker, exchange, address) but no financial statements, MD&A, guidance, risks, or operational commentary. As a result, it is not directly actionable for trading beyond confirming the filing exists.
SOUN 10-Q report for 2026-03-31
The provided excerpt is only the cover/filing header of SoundHound AI, Inc.’s 10‑Q for the quarter ended 2026‑03‑31. It contains listing/security identifiers (SOUN, SOUNW) but no financial statements, MD&A, guidance, risk updates, liquidity details, or material events. As a result, there is insufficient information to form high-confidence, actionable bullish/bearish theses beyond generic “company filed its 10‑Q” metadata.
WEAT 10-Q report for 2026-03-31
The provided excerpt is only the boilerplate cover/filing-status section of Teucrium Commodity Trust’s Form 10‑Q for period ended 2026‑03‑31, with no portfolio holdings, performance, risk, or material updates included. As-is, it contains no actionable investment information beyond confirming the existence of the filing and the issuer/ticker identity (WEAT).
Proof-backed call history
These are recent thesis calls tied to original source content where available.
The provided text is only the cover/header portion of AbCellera Biologics Inc.’s Form 10‑Q for the quarter ended March 31, 2026 (identifying info, exchange listing, filing status). It contains no financial statements, guidance, risk updates, material events, MD&A, cash runway, pipeline/program updates, or disclosures that would support a differentiated trading view.
The provided 10-K text is only the cover page/registrant identifiers for AbCellera Biologics Inc. (ABCL) for FY ended 2025-12-31. It contains no financial statements, MD&A, risk factor changes, guidance, segment detail, liquidity/cash runway, pipeline/program updates, or other disclosures that would support a directional investment view.
The provided text is only the cover/header portion of AbCellera Biologics Inc.’s Form 10-Q for the quarter ended Sep 30, 2025. It confirms the issuer (ABCL), exchange listing (Nasdaq), and that it indicates timely filing/compliance checks, but contains no financial statements, MD&A, risk-factor updates, guidance, or material events. Actionability is therefore very limited.
The provided text is only the cover/header portion of AbCellera Biologics Inc. (ABCL) Form 10-Q for the quarter ended June 30, 2025. It confirms the filing type, period, exchange listing, and reporting compliance checkboxes, but contains no financial statements, MD&A, cash runway, guidance, pipeline/partnership updates, or risk-factor changes. As provided, it is not actionable for trading beyond confirming routine SEC compliance.
About this channel
Channel bio, source link, and public-market context from YouTube.
SEC EDGAR quarterly and annual company filings
Most recognized assets
Unlock the full track record
Create an account to inspect the complete author history, trust-weighted rankings, and persisted research across authors, theses, and assets.